SGSergio Contreras Garduño

Sergio Contreras Garduño

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sergio Contreras Garduño has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Adrian Soto-Mota

    Metabolic Diseases Research Unit, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    1 shared publication
  • Daniel Aillaud‐De‐Uriarte

    Center for Bioethics Harvard Medical School Boston Massachusetts USA

    1 shared publication
  • Eduardo Gutiérrez-León

    Affiliation Department of Medical Education, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    1 shared publication
  • Eduardo Gutiérrez-León

    Faculty of Medicine, Universidad Nacional Autónoma de México, Circuito de Posgrados s/n, Ciudad Universitaria, Coyoacán, Mexico City 04510, Mexico; Departamento de Hematología y Oncología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Belisario Domínguez Secc. 16, Tlalpan, Mexico City 14080, Mexico

    1 shared publication
  • Enrique Soto-Perez-De-Celis

    Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

    1 shared publication
  • Erick Yasar Zúñiga-González

    Affiliation Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    1 shared publication

Latest Publications

  • Open Access

    Outcomes in acute pulmonary embolism and their association with adherence to international recommendations around COVID-19 pandemic-induced hospital-strain: The experience in a Mexican tertiary care center

    by Juan José Rodríguez-Crespo, Eduardo Gutiérrez-León, Pedro Dammann-Beltrán, Jurhiat Alejandro Seaman-Gómez, Sergio Contreras-Garduño, Erick Yasar Zúñiga-González, José Guillermo Domínguez-Cherit, Thierry Hernández-Gilsoul, José de Jesús Vidal-Mayo, Fausto Alfredo Ríos Olais, et al.

    Background: Lack of adherence to international recommendations leads to worse outcomes. During the COVID-19 pandemic, the total number and proportion of hospitalized patients increased, consequently straining hospital care and hindering adherence. Aims: To evaluate adherence to clinical guidelines at our center, before, during, and shortly after the COVID-19 pandemic-induced hospital strain, and its association with clinical outcomes, using a random, balanced retrospective cohort. Design: A balanced and randomized sample of 50 patients per year between 2019 and 2022 was drawn from electronic medical records and analyzed with multivariable and logistic regression models. The primary outcome was a composite of in-hospital death, hemodynamic decompensation within the first 7 days, and in-hospital bleeding. Results: The global non-adherence in our study was 45.4%. The main risk factors for non-adherence were any mortality risk classification above low-risk PE and a PESI class different from class I, with ORs of 3.47 (95% CI 2.07–5.82) and 1.57 (95% CI 1.04–2.37), respectively. In both periods (COVID-19 season and non-COVID-19 season), non-adherent management strongly correlated with the composite outcome, OR = 2.36 (95% CI, 1.23–4.54). Non-adherence was also associated with worse in-hospital outcomes, with an incidence rate of the composite outcome of 21.08 per 1000 days/person (95% CI 10.97–40.51) and 47.7 per 1000 days/person (95% CI 33.39–67.50), and an attributable risk of 1.09% (95% CI −8.47%−10.64%). Conclusions: Overall, our findings highlight the need to prioritize human and material resources to ensure adherence to the standards of care for PE patients.

  • Trends in Cervical Cytology Test Reports and Cervical Dysplasia Severity according to Social Deprivation in Mexico (2013–2019): An Analysis of a National Database

    by Sergio Contreras Garduño, Valeria Saraiba-Rabanales, Yanin Chavarri-Guerra, Enrique Soto-Perez-De-Celis

    Background: Cervical cancer is a leading cause of cancer-related mortality in women living in low- and middle-income countries such as Mexico. Preventive and screening programs are often inaccessible to socially deprived populations, whose limited access to timely diagnosis and treatment reduces the chance of detecting premalignant lesions early. Methods: Cervical malignant and premalignant lesion positivity rates were analyzed from 2013 to 2016 using the Bethesda system, whereas human papillomavirus (HPV) positivity rates were analyzed from 2017 to 2019. Both were stratified according to state-level Social Deprivation Indices in Mexico, published by the National Council for the Evaluation of Social Development Policy. The data originated from the four main healthcare providers in Mexico. Data processing and statistical analyses were performed using Joinpoint Regression Software and SPSS version 25. Results: Positivity rates for dysplasia and atypia varied across social deprivation levels. A downward trend in premalignant lesion positivity rates was observed. This varied across social deprivation groups, with differing annual percentage changes (APC). The greatest decrease occurred in high-grade cervical intraepithelial dysplasia (CIN 2–3) in states with very high social deprivation, with an estimated APC of −22.1% (−30% to −14.7%; P = 0.001). HPV positivity by PCR ranged from 11% to 24% between 2017 and 2019. The estimated APC for invasive cervical carcinoma was −22.3% [95% confidence interval (CI); −54.4% to 19.8%], which was not statistically significant (P = 0.223). Conclusions: Our study highlights a decline in cervical dysplasia positivity rates. These declines were uneven across social deprivation levels. Impact: Reducing health inequities is essential to prevent, detect, and treat cervical cancer and its precursors.

  • Assessment of Challenging Oncologic Cases: A Comparative Analysis Between ChatGPT, Gemini, and a Multidisciplinary Tumor Board

    by Luis A. Hernández‐Flores, José B. López‐Martínez, Jesús J. Rosales‐De‐La‐Rosa, Daniel Aillaud‐De‐Uriarte, Sergio Contreras‐Garduño, Rubén Cortés‐González

    Introduction: Since its introduction in 2022, public‐access conversational AI, exemplified by ChatGPT and Gemini, has been increasingly utilized in medical decision‐making, though its impact is questionable. This study aims to evaluate its efficacy in assessing complex oncologic cases compared to a multidisciplinary tumor board (MTB) comprising experts from various specialties.Methods: A 2‐year retrospective analysis was conducted on 98 oncological cases at a reference medical center in Mexico City. A MTB comprising surgical oncologists, medical oncologists, radio‐oncologists, pathologists, among others, reviewed and discussed each case to determine management strategies. We evaluated four key decision points, dichotomized as either affirmative or negative: the need for new imaging studies, radiation therapy, chemotherapy, and surgery. Comprehensive medical documentation accompanied each case. We then compared AI's decisions with those of the MTB using the same criteria and conducted a Cohen's Kappa test to assess agreement.Results: Agreement between ChatGPT (4o) and Gemini (1.5 Flash), and the MTB ranged from none to slight for additional imaging studies (Gemini: κ = 0.100, p = 0.087; ChatGPT 4o: κ = 0.024, p = 0.592) and chemotherapy (Gemini: κ = 0.089, p = 0.316; ChatGPT 4o: κ = 0.336, p = 0.001). Moderate agreement was observed for decisions regarding surgery (Gemini: κ = 0.194, p = 0.046; ChatGPT 4o: κ = 0.467, p = < 0.001) and radiotherapy (Gemini: κ = 0.214, p = 0.012; ChatGPT 4o: κ = 0.525, p = < 0.001).Conclusions: Both ChatGPT and Gemini showed moderate agreement with the multidisciplinary tumor board on decisions regarding surgery and radiotherapy. ChatGPT also showed moderate agreement in chemotherapy, but further assessment is needed for other interventions. ChatGPT proved to be superior to Gemini in most key points. The potential of these public access AI in oncology warrants continued exploration to refine its utility in clinical practice.